Including agents that target EGFR, PDGFR, and FGFR in anti-VEGF therapy can also improve the efficacy of cancer treatment by rewiring multiple cellular pathways and minimizing drug resistance in ovarian and other cancers [89,378,379]. The gene discussed is PDGFRB; the disease is cancer.